Le livre est actuellement en rupture de stock
En savoir plus sur le livre
The book explores the differences between regulatory agencies and health technology assessment (HTA) bodies in evaluating new medicines. It highlights how HTA bodies require additional evidence for reimbursement decisions, which can vary by country and include factors like unmet medical needs and cost-effectiveness. The text discusses the challenges posed by the evidence gap between regulatory approval and reimbursement, which can delay patient access to new drugs. It emphasizes the importance of early collaboration among industry, regulatory authorities, and reimbursement agencies in the drug development process.
Achat du livre
EMA-HTA Parallel Scientific Advice: Challenges and Opportunities, Ulrike Fuchs
- Langue
- Année de publication
- 2017
- product-detail.submit-box.info.binding
- (souple)
Nous vous informerons par e-mail dès que nous l’aurons retrouvé.
Modes de paiement
Personne n'a encore évalué .